Inhibiting Macrophage Matrix Vesicle Calcification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical therapies are ineffective in preventing or inhibiting cardiovascular calcification, particularly arterial and valvular microcalcification, which poses a significant risk for cardiovascular events and mortality, with no available treatments for calcification-related conditions like aortic valve stenosis and chronic renal disease.
Innovation Solution
A method involving compounds that inhibit the release or formation of calcifying matrix vesicles from macrophages by targeting phosphatidylserine, annexin II, V, or VI, and S100A9/S100A12, reducing their expression or complex formation, thereby decreasing calcification potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current medical therapies (statins, mineralocorticoid receptor antagonists) are used to target cardiovascular calcification, then treatment options are available, but they have not proved beneficial in the clinical setting
Solution Approach 1:
The patent extracts and targets the specific mechanism of matrix vesicle release and calcification by macrophages, separating this pathway from general cardiovascular protection mechanisms. By focusing on matrix vesicle-derived S100A9/S100A12 proteins and phosphatidylserine-annexin complexes, the invention identifies a specific actionable target that differs from conventional broad-spectrum therapies like statins and mineralocorticoid receptor antagonists.
Solution Approach 2:
The patent introduces matrix vesicles as intermediary structures that mediate the calcification process. These vesicles contain S100A9/S100A12 proteins and phosphatidylserine-annexin complexes that serve as the actual effector molecules for calcium deposition. Targeting these intermediary elements provides a more precise mechanism for preventing calcification compared to conventional therapies.
2Reliability
If surgical valve replacement is used to treat aortic valve calcification or stenosis, then effective treatment is achieved, but many patients with advanced calcification and impaired cardiac function have no indication
Solution Approach 1:
The patent enables preliminary intervention to prevent calcification before it reaches advanced stages requiring surgery. By targeting matrix vesicle release and the formation of calcification-nucleating complexes early in the process, the therapy can prevent or slow calcification progression, making more patients eligible for non-surgical management and reducing the need for valve replacement in those with impaired cardiac function.
3Productivity
If matrix vesicles are released by macrophages to initiate mineralization, then calcification process is activated, but this pathway is not currently targetable by existing therapies
Solution Approach 1:
The patent identifies specific molecular parameters (S100A9/S100A12 protein expression, phosphatidylserine-annexin complex formation) that can be modulated by therapy. By changing the expression levels or activity of these specific proteins and complexes, the calcification process can be inhibited without requiring non-specific or broadly acting therapies.
Data Source
AI summary
The invention relates to methods for decreasing, inhibiting, preventing, or reducing matrix vesicle induced calcification by inhibiting the amount or formation of a complex comprising phosphatidylserine (PS), annexin II, annexin V or VI, and S100A9 or S100A12 in a macrophage.